Docoh
Loading...

NXTC Nextcure

News

From Benzinga Pro
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
75 Biggest Movers From Yesterday
10 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Society Pass Incorporated (NASDAQ: SOPA) surged 436.7% to settle at $48.30 on Tuesday after the company priced its IPO at $9 per share.
58 Stocks Moving In Tuesday's Mid-Day Session
9 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash.
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
8 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Needham Maintains Buy on NextCure, Lowers Price Target to $14
5 Nov 21
News, Price Target, Analyst Ratings
Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $30 to $14.
NextCure Q3 EPS $(0.65) Down From $(0.59) YoY
4 Nov 21
Earnings, News
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.65) per share. This is a 10.17 percent decrease over losses of $(0.59) per share from the same period last year.

Press releases

From Benzinga Pro
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
13 Dec 21
News, Press Releases
BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
NextCure to Present at The JMP Securities Hematology and Oncology Summit
30 Nov 21
News, Press Releases
BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting
13 Nov 21
News, Health Care, Analyst Ratings, Press Releases
BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update
4 Nov 21
Earnings, Press Releases
BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting
4 Nov 21
News, Press Releases
BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021
1 Nov 21
News, Press Releases
BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer